Home › Burkitt Lymphoma › Tennessee › Nashville
Burkitt Lymphoma clinical trials in Nashville, TN
8 studies for Burkitt Lymphoma are looking for participants at sites in and around Nashville (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
RecruitingPhase 2
- The Children's Hospital at TriStar Centennial, Nashville
- Vanderbilt University/Ingram Cancer Center, Nashville
Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
RecruitingPhase 2
- The Children's Hospital at TriStar Centennial, Nashville
- Vanderbilt University/Ingram Cancer Center, Nashville
A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
RecruitingPhase 2
- The Children's Hospital at TriStar Centennial, Nashville
- Vanderbilt University/Ingram Cancer Center, Nashville
Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
RecruitingPhase 3
- The Children's Hospital at TriStar Centennial, Nashville
- Vanderbilt University/Ingram Cancer Center, Nashville
Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
RecruitingPhase 1/2
- TriStar BMT, Nashville
Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Acute Lymphoblastic Leukemia
RecruitingPhase 1/2
- Research Site, Franklin · 17 mi away
Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)
RecruitingPhase 1/2
- Sarah Cannon - HCA Research Institute, Nashville
Study of VIP943 in Subjects With Advanced CD123+ Hematologic Malignancies
RecruitingPhase 1
- TriStar Bone Marrow Transplant, Nashville
Burkitt Lymphoma trials in other cities
- Houston, TX21 studies
- Philadelphia, PA16 studies
- Milwaukee, WI16 studies
- Chicago, IL15 studies
- New York City, NY13 studies
- Cincinnati, OH13 studies
- Atlanta, GA12 studies
- Aurora, CO11 studies
- Seattle, WA11 studies
- Durham, NC10 studies
- Kansas City, MO10 studies
- Boston, MA10 studies
Other studies in Nashville
- Non-Small Cell Lung Cancer97 studies
- Breast Cancer81 studies
- Metastatic Cancer70 studies
- Colorectal Cancer69 studies
- Cancer (all types)65 studies
- Ovarian Cancer49 studies
- Prostate Cancer43 studies
- Lung Cancer40 studies
- Head and Neck Squamous Cell Carcinoma39 studies
- Pancreatic Cancer39 studies
- Endometrial Cancer38 studies
- Melanoma33 studies
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.